Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL670004 | 1.00 | PLA2G7 (0.54) | PLA2G7SMN1; SMN2LMNARECQLATM | |
| SCHEMBL14077931 | 0.85 | PLA2G7 (0.53) | PLA2G7SMN1; SMN2LMNARECQLATM | |
| SCHEMBL12705075 | 0.85 | SMN1; SMN2 (0.54) | PLA2G7SMN1; SMN2LMNARECQLATM | |
| SCHEMBL13025225 | 0.85 | SMN1; SMN2 (0.54) | PLA2G7SMN1; SMN2LMNARECQLATM | |
| SCHEMBL8613027 | 0.84 | ATM (0.59) | PLA2G7SMN1; SMN2LMNAATMHTT | |
| SCHEMBL8291064 | 0.84 | ATM (0.59) | PLA2G7SMN1; SMN2LMNAATMHTT | |
| SCHEMBL11406469 | 0.83 | MEN1 (0.62) | SMN1; SMN2LMNAATMHTTL3MBTL1 | |
| SCHEMBL14262671 | 0.82 | SMN1; SMN2 (0.49) | PLA2G7SMN1; SMN2LMNARECQLATM | |
| SCHEMBL19296378 | 0.81 | SMN1; SMN2 (0.51) | PLA2G7SMN1; SMN2LMNARECQLATM | |
| SCHEMBL17831026 | 0.81 | SMN1; SMN2 (0.70) | PLA2G7SMN1; SMN2LMNARECQLATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2795317-B1 | Composition for use in a method for cancer selection | GE HEALTHCARE LTD (GB) | 2018-05-30 | — | — | EP | disclosed |
| US-9956303-B2 | Anti-met therapy for previously diagnosed cancer patients | GE HEALTHCARE LIMITED (GB) | 2018-05-01 | — | — | US | disclosed |
| EP-2605802-B1 | PEPTIDE RADIOTRACER COMPOSITIONS | GE HEALTHCARE LTD (GB) | 2017-04-26 | — | — | EP | disclosed |
| US-9533059-B2 | Peptide radiotracer compositions | GE HEALTHCARE LIMITED (GB) | 2017-01-03 | — | — | US | disclosed |
| US-20140335022-A1 | METHOD FOR PATIENT SELECTION | GE HEALTHCARE LIMITED (GB) | 2014-11-13 | — | — | US | disclosed |
| EP-2795317-A1 | METHOD FOR PATIENT SELECTION | GE Healthcare UK Limited (GB) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013092742-A1 | METHOD FOR PATIENT SELECTION | GE HEALTHCARE LIMITED (GB) | 2013-06-27 | — | — | WO | disclosed |
| EP-2605802-A1 | PEPTIDE RADIOTRACER COMPOSITIONS | GE Healthcare Limited (GB) | 2013-06-26 | — | — | EP | disclosed |
| US-20130149241-A1 | PEPTIDE RADIOTRACER COMPOSITIONS | GE HEALTHCARE LIMITED (GB) | 2013-06-13 | — | — | US | disclosed |
| WO-2012022676-A1 | PEPTIDE RADIOTRACER COMPOSITIONS | GE HEALTHCARE LIMITED (GB) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335022-A1 | METHOD FOR PATIENT SELECTION | MET, HGF, METAP1 | PLA2G7 3453/4885SMN1; SMN2 4350/4885LMNA 4666/4885 |
| US-20130149241-A1 | PEPTIDE RADIOTRACER COMPOSITIONS | MET, GRPR, MEN1 | PLA2G7 4208/4885SMN1; SMN2 4412/4885LMNA 3792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.